Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy

Fig. 3

Tagln2−/− DCs showed impaired migration into the lymph node. a Expression of chemokine receptors and adhesion molecules in WT or Tagln2−/− DCs. The in vitro migration assay was performed using a Boyden chamber, and the number of migrating cells was counted by flow cytometry. b Time-lapse imaging of WT or Tagln2−/− DCs on Fn in response to CCL19 (200 ng/mL). Representative morphology was categorized into three groups according to projection, spreading, and migration. Normal protrusions and irregular membrane morphology in WT or Tagln2−/− DCs are indicated as blue and red arrows, respectively. Scale bar, 10 μm. c Schematic diagram of the experimental setup for c and d. c, d The same number of WT (green) or Tagln2−/− DCs (red) was injected into the footpads of WT recipient mice, and the number of migratory cells in the draining popliteal LNs was analyzed by flow cytometry (c) and fixed cryosections (d). Anti-B220 was used to distinguish the B cell zone. Scale bar, 100 μm. All data represent the mean of three experiments ± SEM. *P < 0.01

Back to article page